Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Parijat Didolkar

Thoracic Surgery (Cardiothoracic Vascular Surgery) Myrtle Beach, SC Medical Doctor

NPI 1821252370 CMS profile 264739

920 Doug White Dr Ste 420, Myrtle Beach, SC 29572

Open in the dashboard

General payments

$20,963

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Parijat Didolkar of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $20,963 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,967 26
2024 General $1,484 23
2023 General $14,084 58
2022 General $829 13
2021 General $213 5
2020 General $162 2
2019 General $2,224 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Parijat Didolkar
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Parijat Didolkar were reported at $1,967. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Parijat Didolkar Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $2,224 $886 $178–$3,167 $163
2020 $162 $341 $108–$1,605 $114
2021 $213 $453 $125–$1,886 $132
2022 $829 $695 $180–$2,566 $149
2023 $14,084 $745 $205–$2,662 $160
2024 $1,484 $799 $214–$2,967 $164
2025 $1,967 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $11,653 37 payments
  2. W. L. Gore & Associates, Inc. $2,780 25 payments
  3. Medtronic, Inc. $1,669 15 payments
  4. Atricure, Inc. $1,425 29 payments
  5. Edwards Lifesciences Corporation $1,236 13 payments
  6. Abiomed $730 5 payments
  7. Abbott Laboratories $475 5 payments
  8. Medtronic Vascular, Inc. $258 7 payments
  9. Peerless Surgical Inc. $166 1 payment
  10. Chiesi USA, Inc. $105 1 payment
  11. Other $468 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $8,500 3 payments
  2. Food and Beverage $7,999 130 payments
  3. Travel and Lodging $4,465 19 payments
Products named General payments · program years 2019–2025
  1. DAVINCI XI $8,500 3 payments
  2. Da Vinci Surgical System $3,153 34 payments
  3. TAG Thoracic Endoprosthesis $1,351 7 payments
  4. ENDURANT IIS $1,310 8 payments
  5. GORE TAG Thoracic Endoprosthesis $1,247 12 payments
  6. SAPIEN 3 Ultra RESILIA $657 4 payments
  7. ATRICLIP LAA EXCLUSION SYSTEM $599 12 payments
  8. SYNERGY ABLATION SYSTEM $471 10 payments
  9. Impella $409 3 payments
  10. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $374 8 payments
  11. Other $2,528 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

95

Median for Psychiatry: 574

Drug cost

$1,381

Median for Psychiatry: $27,624

Branded share of claims

0%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enoxaparin Sodium Generic 15 $942
Mupirocin Generic 80 $439

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$227,982

Medicare's payments for the services billed

Medicare patients

242

Average age 76

Services billed

664

82 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 63%
Arthritis 56%
Atrial fibrillation 45%
Diabetes 37%
Chronic kidney disease 31%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record